Nautilus Biotechnology Inc. recently stated that the company does not expect to generate substantial revenue from early access program collaborations before 2026.

This statement reveals the phased characteristics of the company's commercialization process, while also reflecting the common revenue challenges faced by biotechnology companies in the early stages of product marketization. As an innovative company focused on the development of proteomics technology, Nautilus is currently still in the stage of technology validation and platform optimization. The early access program, serving as an important bridge between technological R&D and commercial application, can accumulate valuable real-world application data, but it is often difficult to generate large-scale revenue in the initial phase of the project. This development model is quite representative in the biotechnology field, as many similar companies have experienced a long cycle from technological accumulation to commercial realization.It is worth noting that this statement does not imply that the company's development has encountered obstacles. On the contrary, it reflects the management's rational expectations and strategic patience regarding the commercialization process. In the biotechnology industry, pursuing revenue scale too early at the expense of technological refinement may actually affect long-term development potential. Nautilus has chosen to prioritize the maturity and reliability of its technology platform, and this prudent strategy is more conducive to building a sustainable competitive advantage.As the application value of proteomics technology in drug development, disease diagnosis, and other fields becomes increasingly prominent, the technological direction that Nautilus focuses on has broad market prospects. The current stage of revenue expectation management actually lays a more solid foundation for future large-scale commercialization. While investors pay attention to short-term revenue indicators, they should also focus on the company's progress in core technology accumulation and long-term value creation.